This study aimed to show the clinical benefit of adding carboplatin to radiation therapy in the postoperative setting. 310 patients were treated, 157 with radiation alone and 153 with concurrent radiation and chemotherapy. 77% had lymph node positive disease. There was no significant difference in disease-free or overall survival. Distant metastases were seen in 7% on both arms. The authors concluded that there is no clinical benefit to the addition of carboplatinum to postoperative radiotherapy.